HER2
22 drugsHuman Epidermal Growth Factor Receptor 2 (ERBB2)
Predictive biomarker for patient selection in 22 indications
Understanding HER2
What it means: HER2 is a receptor tyrosine kinase that promotes cell growth. Overexpression or gene amplification drives aggressive cancer behavior.
Why it matters: HER2+ cancers respond to targeted therapies: trastuzumab (Herceptin), pertuzumab, T-DXd (Enhertu), and lapatinib.
Testing: IHC for protein expression (0, 1+, 2+, 3+) and FISH for gene amplification. 3+ or FISH+ is considered HER2-positive.
22
Approved Drugs
22
Indications
16
Companies
Search HER2 Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting HER2
| Drug | Company | Therapeutic Area |
|---|---|---|
| BIZENGRI | MERUS N.V. | Oncology |
| ENHERTU | DAIICHI SANKYO | Oncology |
| GILOTRIF | Boehringer Ingelheim | Oncology |
| HERCEPTIN | Roche | Oncology |
| HERCEPTIN HYLECTA | Roche | Oncology |
| HERNEXEOS | Boehringer Ingelheim | Oncology |
| HERZUMA | CELLTRION INC | Oncology |
| HYRNUO | Bayer | Oncology |
| KADCYLA | Roche | Oncology |
| KANJINTI | Amgen | Oncology |
| MARGENZA | MACROGENICS INC | Oncology |
| NERLYNX | PUMA BIOTECH | Oncology |
| OGIVRI | Viatris | Oncology |
| ONTRUZANT | SAMSUNG BIOEPIS CO LTD | Oncology |
| PERJETA | Roche | Oncology |
| PHESGO | Roche | Oncology |
| TAGRISSO | AstraZeneca | Oncology |
| TRAZIMERA | Pfizer | Oncology |
| TUKYSA | SEAGEN | Oncology |
| TYKERB | Novartis | Oncology |
| VIZIMPRO | Pfizer | Oncology |
| ZIIHERA | JAZZ PHARMS | Oncology |
Indications
Non-Small Cell Lung Cancer Breast Cancer Unresectable or metastatic HER2-positive breast cancer Unresectable or metastatic hormone receptor-positive, HER2-low or HER2-ultralow breast cancer Unresectable or metastatic HER2-low breast cancer Unresectable or metastatic HER2-mutant non-small cell lung cancer Locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma HER2-overexpressing adjuvant breast cancer HER2-overexpressing metastatic breast cancer HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma Gastric Cancer Gastroesophageal Junction Adenocarcinoma Metastatic Breast Cancer Adjuvant therapy after tumor resection in adult patients with EGFR exon 19 deletions or exon 21 L858R mutation-positive non-small cell lung cancer (NSCLC) Locally advanced, unresectable (stage III) EGFR exon 19 deletions or exon 21 L858R mutation-positive NSCLC that has not progressed during or following platinum-based chemoradiation therapy First-line treatment of adult patients with metastatic EGFR exon 19 deletions or exon 21 L858R mutation-positive NSCLC First-line treatment of adult patients with locally advanced or metastatic EGFR exon 19 deletions or exon 21 L858R mutation-positive NSCLC, in combination with pemetrexed and platinum-based chemotherapy Metastatic EGFR T790M mutation-positive NSCLC in patients whose disease has progressed on or after EGFR tyrosine kinase inhibitor therapy Colorectal Cancer Early Breast Cancer Pancreatic Adenocarcinoma Biliary Tract Cancer